You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Investigational Drug Information for UGN-102


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for UGN-102?

UGN-102 is an investigational drug.

There have been 4 clinical trials for UGN-102. The most recent clinical trial was a Phase 2 trial, which was initiated on February 19th 2021.

The most common disease conditions in clinical trials are Carcinoma, Transitional Cell, Carcinoma, and Urinary Bladder Neoplasms. The leading clinical trial sponsors are UroGen Pharma Ltd. and [disabled in preview].

There are five hundred and eighty-two US patents protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for UGN-102
TitleSponsorPhase
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerUroGen Pharma Ltd.Phase 3
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)UroGen Pharma Ltd.Phase 3
A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerUroGen Pharma Ltd.Phase 3

See all UGN-102 clinical trials

Clinical Trial Summary for UGN-102

Top disease conditions for UGN-102
Top clinical trial sponsors for UGN-102

See all UGN-102 clinical trials

US Patents for UGN-102

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
UGN-102 ⤷  Try a Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC) ⤷  Try a Trial
UGN-102 ⤷  Try a Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Try a Trial
UGN-102 ⤷  Try a Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN) ⤷  Try a Trial
UGN-102 ⤷  Try a Trial Compounds as NIK inhibitors Janssen Pharmaceutica NV (Beerse, BE) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for UGN-102

Drugname Country Document Number Estimated Expiration Related US Patent
UGN-102 World Intellectual Property Organization (WIPO) WO2015148714 2034-03-25 ⤷  Try a Trial
UGN-102 Canada CA2961033 2034-09-11 ⤷  Try a Trial
UGN-102 European Patent Office EP3192791 2034-09-11 ⤷  Try a Trial
UGN-102 Japan JPWO2016039408 2034-09-11 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.